Powder: -20°C for 3 years | In solvent: -80°C for 1 year
(S)-BI 665915 is an orally active inhibitor of oxadiazole-containing 5-lipoxygenase-activating protein (FLAP)(IC50 of 1.7 nM for FLAP binding)..
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 8-10 weeks | $ 1,970.00 | |
50 mg | 8-10 weeks | $ 2,580.00 | |
100 mg | 8-10 weeks | $ 3,400.00 |
Description | (S)-BI 665915 is an orally active inhibitor of oxadiazole-containing 5-lipoxygenase-activating protein (FLAP)(IC50 of 1.7 nM for FLAP binding).. |
Targets&IC50 | FLAP:1.7 nM , FLAP functional (human whole blood):45 nM |
In vitro | (S)-BI 665915 shows significantly weaker activity in mouse whole blood (mWB) assay than in human whole blood (mWB with IC50 of 4800 nM; hWB with IC50 of 45 nM). (S)-BI 665915 shows a modest human hepatocyte clearance (41% percent of hepatic blood flow) and relatively high plasma protein binding (unbound fraction of 4.7%). |
In vivo | (S)-BI 665915 (single oral dose; 1-100 mg/kg;2 h) demonstrates dose-dependent LTB4 production inhibition in mouse whole blood . (S)-BI 665915 (iv of 1 mg/kg or po of 10 mg/kg) shows low iv plasma clearance in all three species, with clearance values of 7 % Qh in rat, 2.8 % Qh in dog, and 3.6 % Qh in cynomolgus monkey, respectively. The volume of distribution (Vss) across species tested is in a range of 0.5 to 1.2 L/kg, and the bioavailability was good (45 to 63 %) in all species tested. |
Molecular Weight | 458.52 |
Formula | C24H26N8O2 |
CAS No. | 1360550-05-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
(S)-BI 665915 1360550-05-5 Others BI 665915 (S) BI 665915 (S)BI 665915 BI-665915 BI665915 inhibitor inhibit